The Diagnostic Significance of Exhaled Nitric Oxide (FeNO) With a Novel Technology in the Assessment of Bronchial Asthma

What this Trial Is About

Researchers are studying a new method for detecting exhaled nitric oxide (FeNO) in the airways, which is important for identifying airway inflammation related to bronchial asthma and other respiratory conditions. This study explores a novel domestic chemiluminescence FeNO analyzer in China that measures FeNO during natural breathing without requiring patient cooperation. This technology aims to improve diagnosis and management for patients who cannot perform standard breathing tests, such as children, elderly, and seriously ill individuals. The study involves two groups: adults diagnosed with bronchial asthma following international criteria and healthy adults without respiratory or allergic diseases. Both groups undergo FeNO testing using two types of analyzers: the new chemiluminescence method and the commonly used electrochemical method. Each participant completes three test sessions per method, with the order randomized, following specific pre-test preparation rules involving medication and activity restrictions. Participants provide demographic and health information and follow pre-test guidelines including medication abstinence and fasting. Testing is conducted during daytime with rest intervals between repeated measurements. Researchers assess the performance of the new analyzer and compare results between the two devices over approximately six months. The goal is to evaluate the consistency and accuracy of this new FeNO detection technology to support better asthma and airway disease diagnosis.

FeNO Detection in Asthma Diagnosis: A New Technology Approach